Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR19-BCMA CAR-T Cell Therapy for Relapsed/Refractory Plasma Cell Neoplasms and Lymphomas/Leukemias
NCT06986434Phase 1Not yet recruiting
- Sponsor
- Academy of Military Medical Sciences
- Start
- Apr 2026
- Primary completion
- May 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR19-BCMA CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences) in plasma cell neoplasm, lymphoma, leukemia and 2 more, sponsored by Academy of Military Medical Sciences. Primary endpoints: Incidence of treatment-related adverse events at 3 years and Maximal Tolerable Dose at 28 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CAR19-BCMA CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences)
03
Conditions
plasma cell neoplasmlymphomaleukemiamultiple myeloma (MM)systemic light chain amyloidosis
Beyond the preview
Go deeper on NCT06986434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986434.